Hayes Timothy Sells 12,000 Health‑In‑Tech Shares Amid Surge of Insider Divestitures as Stock Slumps 69% Year‑to‑Date.

Insider Selling on a Slowing Stock

The latest Rule 144 filing from Health In Tech Inc. shows that director Hayes Timothy sold 12,000 shares of the company’s Class A common stock on 14 September 2026. The transaction was priced at a weighted average of $0.89 per share, a figure that sits just above the current market close of $0.889. The sale comes amid a broader pattern of insider divestments that have punctuated the company’s stock price in recent months, with the share price sliding 4.4 % over the week, 11.9 % over the month, and a staggering 69 % decline over the year. The market cap of roughly $59 million and a negative P/E of –13.87 suggest a valuation that has been dragged down by both fundamentals and sentiment, and the timing of this sale—right after a dip to a 52‑week low of $0.85—raises questions about confidence among those closest to the company.

What It Means for Investors

For the average shareholder, the sale is one more data point indicating that insiders are reducing exposure rather than taking positions. In a market that has been volatile and has seen a sharp decline, this could reinforce a bearish narrative. However, the transaction size is modest relative to the overall market capitalization, and the price range of the sale ($0.8694–$0.943) is narrow, suggesting that the sale was part of a planned, Rule 10b5‑1‑type divestiture rather than a panic sale. The broader insider activity—chief executives and CFOs have also been selling large blocks—could indicate that the company’s leadership is re‑balancing personal portfolios or preparing for potential restructuring. For investors, the prudent approach is to monitor whether these sales are accompanied by any new guidance or strategic shifts rather than treating them as a direct signal of decline.

Hayes Timothy’s Transaction Profile

Hayes Timothy’s insider history is characterized by a mix of purchases and sales that roughly balance out over time. In July 2026, he bought nearly 19,000 shares at $1.06, then sold 12,000 shares at $0.91 in early September, followed by another sale of 5,730 shares at $0.93. Earlier this year, he bought 13,598 shares at $1.36 in April and purchased 5,730 shares at $3.49 in October, but also sold 28,159 shares at $0.00 (a nominal price for a block transaction). His activity suggests a willingness to take both long and short positions, often aligning with company events such as earnings releases or regulatory filings. The recent trend—selling a block of shares when the stock is near a 52‑week low—could be interpreted as a strategic decision to lock in value before a potential rebound, or simply a continuation of a systematic exit plan.

Contextualizing the Broader Insider Trend

Health In Tech’s insiders have been very active in the last six months. The CEO and CFO sold over 70,000 shares each in August and July, and the Chief Growth Officer sold more than 20,000 shares across several transactions. These moves are often executed at similar price points, indicating a systematic plan rather than opportunistic timing. The net effect is a gradual dilution of insider holdings, which could be a precursor to an upcoming change in company direction, a planned capital‑raising event, or simply a normal portfolio re‑balancing. For investors, the key question is whether these sales are a sign of waning confidence or a routine exercise in portfolio management.

Bottom Line

The sale of 12,000 shares by Hayes Timothy is a routine insider divestiture that fits the broader pattern of selling activity at Health In Tech. While it may reinforce bearish sentiment in a stock that is already struggling, the size of the transaction and the narrow price range suggest it is part of a pre‑planned exit strategy. Investors should watch for any accompanying corporate announcements or strategic shifts that might explain the timing, but as of now the move is unlikely to have a material impact on the company’s valuation trajectory.